

# Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

NCT07145229

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Atom Therapeutics Co., Ltd
Enrollment	380 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- Age 18-70 years old (inclusive), male or female.
- Body mass index (BMI) 18-40 kg/m<sup>2</sup> (inclusive).
- Medical history and current findings consistent with diagnosis of gouty arthritis.
- Subjects must have experienced 2 or more gout flares within 12 months prior to screening.
- Onset of an acute gout flare, within 6 months

... and 2 more (see full listing online)

### Exclusion (16)

- Subjects are excluded from the study if one or more of the following criteria are met:
- Administration of oral prednisone e 10 mg or equivalent doses of other glucocorticoids, or use of narcotics, within 24 hours prior to first dose of study drug, or intramuscular, intravenous, or intra-articular injection of any glucocorticoid within 14 days prior to first dose of study drug.
- Use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) prior to first dose dose of study drug, at the investigator's discretion.
- Administration of colchicine or ABP-745 within 14 days prior to first dose of study drug.
- Subjects took any investigational drug in any clinical study within 1 month prior to first dose of study drug and throughout the study period.

... and 11 more (see full listing online)

## Locations (38 total)

---

Onyx Clinical Research, Peoria, Arizona, United States  
Exinia Research, La Mesa, California, United States  
Evergreen Clinical Trial, Norcross, Georgia, United States  
... and 35 more locations